title: Meeting report of the 5th Heidelberg Myeloma Workshop: current status and developments in diagnosis and therapy of multiple myeloma.
abstract: OBJECTIVE
  The 5th Heidelberg Myeloma Workshop was held on April 24 and 25, 2015, in the lecture hall of the department of internal medicine of the University Hospital of Heidelberg, Germany.
  
  
  RESULTS
  Main topics of the meeting were (1) new insights into biology of plasma cell diseases, (2) familial risk in multiple myeloma (MM), (3) diagnosis and prognostic factors in MM and early plasma cell diseases, (4) frontline therapy in transplant-eligible and (5) transplant-ineligible patients as well as (6) treatment of relapsed disease.
  
  
  CONCLUSIONS
  Better understanding of disease biology led to tremendous changes in the treatment of multiple myeloma in recent years and were reported during the meeting.
authors.affiliation: Department of Hematology, Oncology and Rheumatology, University Hospital of Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany. maximilian.merz@med.uni-heidelberg.de.
authors.forename: Maximilian
authors.initials: M
authors.lastname: Merz
authors.affiliation: Department of Hematology, Oncology and Rheumatology, University Hospital of Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.
authors.forename: Jens
authors.initials: J
authors.lastname: Hillengass
authors.affiliation: Department of Hematology, Oncology and Rheumatology, University Hospital of Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.|National Center for Tumor Diseases, Heidelberg, Germany.
authors.forename: Hartmut
authors.initials: H
authors.lastname: Goldschmidt
mesh_terms: D005858:Germany; D006801:Humans; D009101:Multiple Myeloma / Q000175:diagnosis* / Q000628:therapy*; D012955:Societies, Medical
keywords: Autologous; Bortezomib; Carfilzomib; Clonal heterogeneity; Daratumumab; Elotuzumab; Imaging; Lenalidomide; Multiple myeloma; Pomalidomide; Stem cell; Transplantation